Voyager Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Voyager Therapeutics's estimated annual revenue is currently $15.9M per year.(i)
  • Voyager Therapeutics received $75.0M in venture funding in November 2017.
  • Voyager Therapeutics's estimated revenue per employee is $99,874
  • Voyager Therapeutics's total funding is $135M.
  • Voyager Therapeutics's current valuation is $108.2M. (January 2022}

Employee Data

  • Voyager Therapeutics has 159 Employees.(i)
  • Voyager Therapeutics grew their employee count by -39% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson's disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Alzheimer's Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data. Contact: Voyager Therapeutics 75 Sidney St. Cambridge, MA 02139 857-259-5340



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Voyager Therapeutics News

2015-04-13 - Voyager Therapeutics Completes $60M Series B Financing

Voyager Therapeutics, a Cambridge, Mass.-based gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), completed a $60m Series B financing. The round was co-led by new investors Brookside Capital and Partner Fund Manageme ...

2019-06-17 - Sanofi, Voyager Therapeutics rejig gene therapy partnership

Shares of Voyager were up 14 percent on the Nasdaq late Monday morning following the news. Shares of Sanofi were down slightly on the Euronext Paris exchange. Under the restructured relationship, Voyager takes worldwide rights to VY-HTT01, a gene therapy in preclinical, lead-selection developme ...

2021-10-06 - Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance

With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the protein shells that envelope a gene therapy and deliver it into a target cell. That strategy is starti ...

09/05/2019 - The Majority of Analysts Are Still Bullish on Voyager ...

On Wednesday, shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) marked $16.77 per share versus a previous $17.11 closing price.

55 menit yang lalu - Voyager Therapeutics Inc (NASDAQ:VYGR) Shares Acquired ...

DekaBank Deutsche Girozentrale lifted its stake in Voyager Therapeutics Inc (NASDAQ:VYGR) by 63.6% in the 2nd quarter, according to the ...

09/05/2019 - Morning Stock Gigantic Turns: Voyager Therapeutics, Inc ...

On Thursday's Current Session, Voyager Therapeutics, Inc. (NASDAQ:VYGR) closing at $17.00 price level during recent trade its distance from ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Voyager Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-02-13$45.0MAThird Rock VenturesArticle
2015-04-14$60.0MBBrookside CapitalArticle
2017-11-08$75.0MUndisclosedMorgan StanleyArticle